Fig. 6

Characterization of tRFAla−AGC−3−M8 and EphA7 expression in in vitro models of AD. (A–D) qRT-PCR analysis of tRFAla−AGC−3−M8 expression in HT22 cells (after 24 h induction with Aβ25–35) and BV-2 cells (after 24, 36, or 48 h induction with Aβ25–35; n = 6, biologically independent samples); Scale bar: 75μm (overview), 20μm (insert). (E, F) Immunofluorescence analysis of iNOS localization in BV-2 cells after 48 h induction with Aβ25–35. The distance–intensity average curve demonstrates the characteristic expression profile of iNOS in BV-2 cells treated with Aβ25–35 (n = 6, biologically independent samples). (G) Measurement of cell length in iNOS + BV-2 cells (n = 6, biologically independent samples); Scale bar: 75μm (overview), 20 μm (insert). (H–J) Western blot analysis of iNOS and EphA7 expression in BV-2 and HT-22 cells following treatment with Aβ25–35 for 24 or 48 h (n = 6, biologically independent samples); Statistical significance was assessed using one-way ANOVA (P values are indicated). All Data are presented as means ± SEM. Each data point represents the average of 3 technical replicates